Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.
Photodynamic therapy (PDT) with verteporfin (Visudyne), a photosensitising protoporphyrin derivative, is used in the management of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) or pathological myopia (PM). PDT with verteporfin over 1 and 2 years reduces the decline in visual acuity in patients with classic-containing subfoveal CNV secondary to AMD. Verteporfin is generally well tolerated by most patients. Verteporfin is also effective in patients with CNV secondary to PM, although data in this indication are limited and further controlled studies are required. Although verteporfin has shown efficacy in patients with occult AMD-related subfoveal CNV lesions in early trials, data are currently limited on its first-line use in this indication; fully published data from the Verteporfin In Occult (VIO) trial are therefore awaited with interest. Verteporfin should be considered as a first-line treatment in patients with predominantly classic subfoveal CNV secondary to AMD, and in patients with smaller minimally classic subfoveal CNV lesions. It may also be considered an option for the treatment of patients with occult AMD-related subfoveal CNV in whom visual acuity decreases or predominantly classic features develop over time.
Fenton
Caroline
C
Adis International Limited, Mairangi Bay, Auckland, New Zealand.
Perry
Caroline M
CM
D000375:Aging; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016206:Databases, Bibliographic; D004363:Drug Utilization; D005123:Eye / Q000187:drug effects; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D047728:Myopia, Degenerative / Q000188:drug therapy; D011166:Porphyrins / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077362:Verteporfin
D011166:Porphyrins; D000077362:Verteporfin